FDA Approves First Treatment for Patients with Fatty Liver Disease

March 27, 2024 // Southern Medical Association

The US Food & Drug Administration (FDA) recently approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with exercise and diet. 

According to the press announcement, "NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation."

Click here to view the FDA's announcement of Rezdiffra's approval.

Posted in: 2024
SMA Menu